These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26683709)

  • 21. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
    Collett K; Eide GE; Arnes J; Stefansson IM; Eide J; Braaten A; Aas T; Otte AP; Akslen LA
    Clin Cancer Res; 2006 Feb; 12(4):1168-74. PubMed ID: 16489070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
    Lee HW; Choe M
    Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
    Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
    Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
    Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
    J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
    Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
    Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
    Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
    Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.
    Reijm EA; Timmermans AM; Look MP; Meijer-van Gelder ME; Stobbe CK; van Deurzen CHM; Martens JWM; Sleijfer S; Foekens JA; Berns PMJJ; Jansen MPHM
    Ann Oncol; 2014 Nov; 25(11):2185-2190. PubMed ID: 25193989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
    Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
    Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.
    Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C
    Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
    Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
    Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
    Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic role of EZH2 in gliomas: a meta-analysis.
    Pyo JS; Kang DW
    Int J Biol Markers; 2018 Jan; 33(1):62-67. PubMed ID: 28862715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.